Vaccine for Kidney Cancer Patients
Author Information
Author(s): Jonasch E, Wood C, Tamboli P, Pagliaro L C, Tu S M, Kim J, Srivastava P, Perez C, Isakov L, Tannir N
Primary Institution: University of Texas MD Anderson Cancer Center
Hypothesis
The study aimed to evaluate the clinical efficacy of the autologous vitespen vaccine in stage IV metastatic renal cell carcinoma patients.
Conclusion
The study found that treatment with vitespen did not result in a discernable benefit for the majority of patients with metastatic renal cell carcinoma.
Supporting Evidence
- Of 60 evaluable patients, 2 demonstrated complete response and 2 showed partial response.
- Median overall survival for all patients was 476 days.
- Adding interleukin-2 did not significantly impact clinical outcomes.
Takeaway
Doctors tested a new vaccine to help kidney cancer patients, but it didn't really work for most of them.
Methodology
Patients underwent nephrectomy and received the vitespen vaccine, with some also receiving interleukin-2, followed by evaluations of their response.
Potential Biases
Potential bias due to the single-center study design and the lack of a control group.
Limitations
The study had a small sample size and many patients did not respond to the treatment.
Participant Demographics
{"median_age":57,"gender_distribution":{"male":78,"female":22},"performance_status":{"0":52,"1":32,"2":13}}
Statistical Information
P-Value
0.017
Confidence Interval
95% CI 249–691 days
Statistical Significance
p=0.017
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website